| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.
|
Lancet
|
2003
|
19.90
|
|
2
|
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.
|
JAMA
|
2003
|
10.55
|
|
3
|
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
|
JAMA
|
2004
|
9.91
|
|
4
|
ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association.
|
Circulation
|
2009
|
5.49
|
|
5
|
ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography).
|
Circulation
|
2007
|
4.66
|
|
6
|
Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
|
N Engl J Med
|
2002
|
4.25
|
|
7
|
Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials.
|
Lancet
|
2006
|
2.92
|
|
8
|
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
|
JAMA
|
2004
|
2.89
|
|
9
|
Integrating complementary medicine into cardiovascular medicine. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (Writing Committee to Develop an Expert Consensus Document on Complementary and Integrative Medicine).
|
J Am Coll Cardiol
|
2005
|
2.71
|
|
10
|
Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial.
|
J Am Coll Cardiol
|
2003
|
2.18
|
|
11
|
Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
|
J Am Coll Cardiol
|
2010
|
2.15
|
|
12
|
Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina?
|
Catheter Cardiovasc Interv
|
2003
|
2.06
|
|
13
|
Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction.
|
Eur Heart J
|
2007
|
1.92
|
|
14
|
Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction.
|
J Am Coll Cardiol
|
2004
|
1.84
|
|
15
|
Simplified scoring system for predicting mortality after percutaneous coronary intervention.
|
J Am Coll Cardiol
|
2003
|
1.84
|
|
16
|
Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification.
|
Am J Cardiol
|
2004
|
1.83
|
|
17
|
Coronary stent restenosis in patients treated with cilostazol.
|
Circulation
|
2005
|
1.73
|
|
18
|
Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
|
J Am Coll Cardiol
|
2011
|
1.72
|
|
19
|
Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial).
|
Am J Cardiol
|
2006
|
1.62
|
|
20
|
Expert consensus statement on the use of fractional flow reserve, intravascular ultrasound, and optical coherence tomography: a consensus statement of the Society of Cardiovascular Angiography and Interventions.
|
Catheter Cardiovasc Interv
|
2013
|
1.56
|
|
21
|
Primary angioplasty in acute myocardial infarction at hospitals with no surgery on-site (the PAMI-No SOS study) versus transfer to surgical centers for primary angioplasty.
|
J Am Coll Cardiol
|
2004
|
1.56
|
|
22
|
Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial.
|
JACC Cardiovasc Interv
|
2009
|
1.54
|
|
23
|
Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score.
|
J Am Coll Cardiol
|
2005
|
1.52
|
|
24
|
Percutaneous coronary interventions in octogenarians. glycoprotein IIb/IIIa receptor inhibitors' safety profile.
|
J Am Coll Cardiol
|
2003
|
1.49
|
|
25
|
Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians.
|
J Am Coll Cardiol
|
2007
|
1.49
|
|
26
|
Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial).
|
Am J Cardiol
|
2005
|
1.47
|
|
27
|
Deformation, longitudinal shortening, and accordion of an ion stent.
|
J Interv Cardiol
|
2011
|
1.47
|
|
28
|
Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial.
|
Circulation
|
2003
|
1.46
|
|
29
|
Rescue angioplasty: does the concept need to be rescued?
|
J Am Coll Cardiol
|
2004
|
1.40
|
|
30
|
Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial.
|
Catheter Cardiovasc Interv
|
2008
|
1.38
|
|
31
|
Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction.
|
Circulation
|
2003
|
1.38
|
|
32
|
Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial).
|
Am J Cardiol
|
2007
|
1.35
|
|
33
|
Diagnosis, management, and clinical outcome of cardiac tamponade complicating percutaneous coronary intervention.
|
Am J Cardiol
|
2002
|
1.31
|
|
34
|
Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials.
|
J Am Coll Cardiol
|
2007
|
1.31
|
|
35
|
Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association.
|
Circulation
|
2005
|
1.30
|
|
36
|
When is door-to-balloon time critical? Analysis from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trials.
|
J Am Coll Cardiol
|
2010
|
1.28
|
|
37
|
Predicting mortality in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention (PAMI risk score).
|
Am J Cardiol
|
2004
|
1.27
|
|
38
|
Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction.
|
Eur Heart J
|
2005
|
1.24
|
|
39
|
Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial.
|
J Am Coll Cardiol
|
2004
|
1.21
|
|
40
|
Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
|
Circulation
|
2005
|
1.19
|
|
41
|
Sustained ventricular tachycardia or fibrillation in the cardiac catheterization laboratory among patients receiving primary percutaneous coronary intervention: incidence, predictors, and outcomes.
|
J Am Coll Cardiol
|
2004
|
1.18
|
|
42
|
Acute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association.
|
Circulation
|
2016
|
1.18
|
|
43
|
Predictors of infarct size after primary coronary angioplasty in acute myocardial infarction from pooled analysis from four contemporary trials.
|
Am J Cardiol
|
2007
|
1.14
|
|
44
|
Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty?
|
J Am Coll Cardiol
|
2004
|
1.13
|
|
45
|
Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
|
Circulation
|
2004
|
1.12
|
|
46
|
Detection of lipid-core plaques by intracoronary near-infrared spectroscopy identifies high risk of periprocedural myocardial infarction.
|
Circ Cardiovasc Interv
|
2011
|
1.12
|
|
47
|
Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: analysis from the CADILLAC trial.
|
Am Heart J
|
2006
|
1.12
|
|
48
|
One-year survival in patients with acute myocardial infarction and a saphenous vein graft culprit treated with primary angioplasty.
|
Am J Cardiol
|
2003
|
1.11
|
|
49
|
Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction.
|
J Am Coll Cardiol
|
2004
|
1.09
|
|
50
|
Magnitude and impact of treatment delays on weeknights and weekends in patients undergoing primary angioplasty for acute myocardial infarction (the cadillac trial).
|
Am J Cardiol
|
2004
|
1.09
|
|
51
|
Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited.
|
Am Heart J
|
2005
|
1.08
|
|
52
|
Impact of body mass index on outcomes after percutaneous coronary intervention in patients with acute myocardial infarction.
|
Am J Cardiol
|
2007
|
1.07
|
|
53
|
Should patients with acute myocardial infraction be transferred to a tertiary center for primary angioplasty or receive it at qualified hospitals in the community? The case for emergency transfer for primary percutaneous coronary intervention.
|
Circulation
|
2005
|
1.07
|
|
54
|
Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
|
J Am Coll Cardiol
|
2003
|
1.05
|
|
55
|
Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: an analysis from the CADILLAC trial.
|
Am Heart J
|
2004
|
1.05
|
|
56
|
Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
|
J Am Coll Cardiol
|
2004
|
1.04
|
|
57
|
Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction.
|
Am Heart J
|
2006
|
1.04
|
|
58
|
Comparison of mortality benefit of immediate thrombolytic therapy versus delayed primary angioplasty for acute myocardial infarction.
|
Am J Cardiol
|
2007
|
1.01
|
|
59
|
Primary percutaneous coronary intervention for every patient with ST-segment elevation myocardial infarction: what stands in the way?
|
Ann Intern Med
|
2004
|
0.98
|
|
60
|
Incidence and prognostic impact of gastrointestinal bleeding after percutaneous coronary intervention for acute myocardial infarction.
|
Am J Cardiol
|
2005
|
0.98
|
|
61
|
Impact and determinants of left ventricular function in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction.
|
Am J Cardiol
|
2005
|
0.95
|
|
62
|
Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
|
Circulation
|
2003
|
0.92
|
|
63
|
Success, safety, and mechanisms of failure of percutaneous coronary intervention for occlusive non-drug-eluting in-stent restenosis versus native artery total occlusion.
|
Am J Cardiol
|
2005
|
0.92
|
|
64
|
Coronary artery pseudoaneurysm after balloon angioplasty and intracoronary beta-radiation for in-stent restenosis.
|
Catheter Cardiovasc Interv
|
2004
|
0.92
|
|
65
|
Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction.
|
J Am Coll Cardiol
|
2005
|
0.91
|
|
66
|
Importance of mitral regurgitation inpatients undergoing percutaneous coronary intervention for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
|
J Am Coll Cardiol
|
2004
|
0.91
|
|
67
|
Relation of admission white blood cell count to long-term outcomes after primary coronary angioplasty for acute myocardial infarction (The Stent PAMI Trial).
|
Am J Cardiol
|
2003
|
0.90
|
|
68
|
Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial.
|
Am Heart J
|
2009
|
0.90
|
|
69
|
SCAI/ACC/AHA Expert Consensus Document: 2014 update on percutaneous coronary intervention without on-site surgical backup.
|
J Am Coll Cardiol
|
2014
|
0.89
|
|
70
|
Relation between leucocyte count, myonecrosis, myocardial perfusion, and outcomes following primary angioplasty.
|
Am J Cardiol
|
2007
|
0.89
|
|
71
|
A percutaneous coronary intervention-thrombolytic predictive instrument to assist choosing between immediate thrombolytic therapy versus delayed primary percutaneous coronary intervention for acute myocardial infarction.
|
Am J Cardiol
|
2008
|
0.89
|
|
72
|
Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial.
|
Arch Intern Med
|
2007
|
0.89
|
|
73
|
Combining antiplatelet and anticoagulant therapies.
|
J Am Coll Cardiol
|
2009
|
0.89
|
|
74
|
Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction.
|
Am Heart J
|
2006
|
0.87
|
|
75
|
The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale.
|
Am Heart J
|
2008
|
0.87
|
|
76
|
Prediction of one-year mortality among 30-day survivors after primary percutaneous coronary interventions.
|
Am J Cardiol
|
2006
|
0.87
|
|
77
|
Analysis of target lesion length before coronary artery stenting using angiography and near-infrared spectroscopy versus angiography alone.
|
Am J Cardiol
|
2011
|
0.87
|
|
78
|
Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
|
Am Heart J
|
2006
|
0.87
|
|
79
|
Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial.
|
J Am Coll Cardiol
|
2004
|
0.86
|
|
80
|
The incidence, predictors, and outcomes of early reinfarction after primary angioplasty for acute myocardial infarction.
|
J Am Coll Cardiol
|
2003
|
0.86
|
|
81
|
Frequency of returning to work one and six months following percutaneous coronary intervention for acute myocardial infarction.
|
Am J Cardiol
|
2004
|
0.86
|
|
82
|
Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction.
|
J Am Coll Cardiol
|
2006
|
0.86
|
|
83
|
Acute angiographic analysis of non-ST-segment elevation acute myocardial infarction.
|
Am J Cardiol
|
2004
|
0.85
|
|
84
|
Off-label use of drug-eluting stents putting it in perspective.
|
J Am Coll Cardiol
|
2008
|
0.85
|
|
85
|
Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction.
|
Am J Cardiol
|
2005
|
0.85
|
|
86
|
Prognostic significance of transient no-reflow during primary percutaneous coronary intervention for ST-elevation acute myocardial infarction.
|
Am J Cardiol
|
2003
|
0.84
|
|
87
|
Editorial: a new beginning and ending?
|
J Interv Cardiol
|
2011
|
0.84
|
|
88
|
Effect of percutaneous coronary intervention on quality of life: a consensus statement from the Society for Cardiovascular Angiography and Interventions.
|
Catheter Cardiovasc Interv
|
2012
|
0.84
|
|
89
|
Mortality in patients with ST-segment elevation myocardial infarction who do not undergo reperfusion.
|
Am J Cardiol
|
2012
|
0.84
|
|
90
|
The year in interventional cardiology.
|
J Am Coll Cardiol
|
2005
|
0.83
|
|
91
|
Effect of door-to-balloon time on patient mortality.
|
J Am Coll Cardiol
|
2006
|
0.83
|
|
92
|
Usefulness of creatinine clearance in predicting early and late death after primary angioplasty for acute myocardial infarction.
|
Am J Cardiol
|
2003
|
0.83
|
|
93
|
Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians.
|
Catheter Cardiovasc Interv
|
2007
|
0.82
|
|
94
|
Does proximal location of culprit lesion confer worse prognosis in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction?
|
J Interv Cardiol
|
2006
|
0.82
|
|
95
|
Vascular endothelial growth factor-165 gene therapy promotes cardiomyogenesis in reperfused myocardial infarction.
|
J Interv Cardiol
|
2008
|
0.81
|
|
96
|
Primary percutaneous coronary intervention: the deception of delay.
|
J Am Coll Cardiol
|
2013
|
0.81
|
|
97
|
A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study.
|
J Am Coll Cardiol
|
2003
|
0.81
|
|
98
|
Procedural success versus clinical risk status in determining discharge of patients after primary angioplasty for acute myocardial infarction.
|
J Am Coll Cardiol
|
2004
|
0.81
|
|
99
|
Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial).
|
Am J Cardiol
|
2004
|
0.81
|
|
100
|
Safety and efficacy of high- versus low-dose aspirin after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
|
JACC Cardiovasc Interv
|
2012
|
0.81
|
|
101
|
SCAI/ACC/AHA Expert Consensus Document: 2014 Update on Percutaneous Coronary Intervention Without On-Site Surgical Backup.
|
Catheter Cardiovasc Interv
|
2014
|
0.80
|
|
102
|
Spontaneous coronary artery dissection.
|
South Med J
|
2008
|
0.80
|
|
103
|
Relation between late patency of the infarct-related artery, left ventricular function, and clinical outcomes after primary percutaneous intervention for acute myocardial infarction (CADILLAC trial).
|
Am J Cardiol
|
2004
|
0.80
|
|
104
|
Basic stenting.
|
J Interv Cardiol
|
2002
|
0.79
|
|
105
|
A nail in the coffin of troponin measurements after percutaneous coronary intervention.
|
J Am Coll Cardiol
|
2011
|
0.79
|
|
106
|
Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial).
|
Am J Cardiol
|
2003
|
0.79
|
|
107
|
Primary coronary intervention for acute myocardial infarction.
|
JAMA
|
2004
|
0.79
|
|
108
|
Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial.
|
Circulation
|
2002
|
0.79
|
|
109
|
Coronary plaque morphology and frequency of ulceration distant from culprit lesions in patients with unstable and stable presentation.
|
Arterioscler Thromb Vasc Biol
|
2003
|
0.79
|
|
110
|
Intracoronary fibrin-specific thrombolytic infusion facilitates percutaneous recanalization of chronic total occlusion.
|
J Am Coll Cardiol
|
2005
|
0.79
|
|
111
|
Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial).
|
Am J Cardiol
|
2003
|
0.79
|
|
112
|
The year in interventional cardiology.
|
J Am Coll Cardiol
|
2009
|
0.79
|
|
113
|
Usefulness of routine unfractionated heparin infusion following primary percutaneous coronary intervention for acute myocardial infarction in patients not receiving glycoprotein IIb/IIIa inhibitors.
|
Am J Cardiol
|
2006
|
0.79
|
|
114
|
Predictors of complete heart block after alcohol septal ablation for hypertrophic cardiomyopathy and the timing of pacemaker implantation.
|
J Interv Cardiol
|
2007
|
0.78
|
|
115
|
Suboptimal inhibition of platelet aggregation following tirofiban bolus in patients undergoing percutaneous coronary intervention for unstable angina pectoris.
|
Am J Cardiol
|
2003
|
0.78
|
|
116
|
A statement on ethics from the HEART Group.
|
JACC Cardiovasc Imaging
|
2008
|
0.78
|
|
117
|
Therapeutic angiogenesis: a fantastic new adventure.
|
J Interv Cardiol
|
2002
|
0.78
|
|
118
|
Panel summary and recommendations on the role of thrombectomy with primary PCI for STEMI.
|
J Invasive Cardiol
|
2010
|
0.77
|
|
119
|
Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up.
|
Circulation
|
2002
|
0.77
|
|
120
|
Transcatheter cardiovascular therapeutics annual meeting.
|
J Interv Cardiol
|
2006
|
0.76
|
|
121
|
Comparison of coronary stenting versus conventional balloon angioplasty on five-year mortality in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
|
Am J Cardiol
|
2005
|
0.76
|
|
122
|
Left ventricular remodeling and systolic deterioration in acute myocardial infarction: findings from the Stent-PAMI Study.
|
J Interv Cardiol
|
2005
|
0.76
|
|
123
|
Primary percutaneous interventions for acute myocardial infarction in octogenarians: a single-center experience.
|
Clin Cardiol
|
2002
|
0.76
|
|
124
|
The current role of AngioJet rheolytic thrombectomy in acute myocardial infarction.
|
J Invasive Cardiol
|
2010
|
0.76
|
|
125
|
Ischemia-driven target vessel revascularization after-primary percutaneous coronary intervention: patients at risk and their outcomes.
|
J Interv Cardiol
|
2005
|
0.76
|
|
126
|
Outcomes of patients consented but not randomized in a trial of primary percutaneous coronary intervention in acute myocardial infarction (the CADILLAC registry).
|
Am J Cardiol
|
2005
|
0.76
|
|
127
|
Sex differences in the drug-eluting stent era: do they still exist?
|
JACC Cardiovasc Interv
|
2012
|
0.75
|
|
128
|
Letter regarding article by Nallamothu et al, "Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United states".
|
Circulation
|
2005
|
0.75
|
|
129
|
Should we routinely use drug-eluting stents for acute myocardial infarction? Let's wait and see.
|
JACC Cardiovasc Interv
|
2008
|
0.75
|
|
130
|
Surgery or stent? The gap continues to narrow.
|
Lancet
|
2002
|
0.75
|
|
131
|
Acute PCI for ST-segment elevation myocardial infarction: is later better than never?
|
JAMA
|
2005
|
0.75
|
|
132
|
Can percutaneous coronary intervention be performed safely as an outpatient procedure?
|
Nat Clin Pract Cardiovasc Med
|
2007
|
0.75
|
|
133
|
Responses to the editor RE: McCullough PA, Roberts WC. Peter Andrew McCullough, MD, MPH: An interview with the editor. Am J Cardiol 2014;114:1772-1785.
|
Am J Cardiol
|
2015
|
0.75
|
|
134
|
Debate: Should the elderly receive thrombolytic therapy, or primary angioplasty, for acute myocardial infarction? The case for primary angioplasty.
|
Curr Control Trials Cardiovasc Med
|
2000
|
0.75
|
|
135
|
Commentary on late breaking trials in interventional cardiology at ESC, VIVA, TCT, AHA (Fall 2012), and ACC 2013.
|
Catheter Cardiovasc Interv
|
2014
|
0.75
|
|
136
|
Commentary on highlighted late breaking trials in interventional cardiology at ESC, VIVA, TCT, and AHA 2013.
|
Catheter Cardiovasc Interv
|
2014
|
0.75
|
|
137
|
Percutaneous coronary intervention versus coronary artery bypass grafting: clinical outcomes in multivessel coronary artery disease.
|
J Interv Cardiol
|
2002
|
0.75
|
|
138
|
Effectiveness of primary angioplasty for acute myocardial infarction in patients on dialysis.
|
Am J Cardiol
|
2004
|
0.75
|
|
139
|
Sex differences in response to treatments for chronic coronary artery disease.
|
Rev Cardiovasc Med
|
2009
|
0.75
|
|
140
|
Acute coronary syndromes: from the emergency department to the catheterization laboratory-integrating evidence from recent ACS/NSTEMI trials into clinical practice: an evidence-based review of recent clinical trial results and report on a roundtable discussion.
|
J Interv Cardiol
|
2010
|
0.75
|
|
141
|
Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction.
|
Am J Cardiol
|
2004
|
0.75
|
|
142
|
Fibrinolytic and mechanical intervention trials in ST elevation acute myocardial infarction.
|
J Interv Cardiol
|
2002
|
0.75
|
|
143
|
Safety of AngioJet thrombectomy in acute ST-segment elevation myocardial infarction: a large, single-center experience.
|
J Invasive Cardiol
|
2006
|
0.75
|
|
144
|
Transradial Coronary Angiogram in a Sitting Position.
|
J Invasive Cardiol
|
2017
|
0.75
|
|
145
|
Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction.
|
J Interv Cardiol
|
2009
|
0.75
|
|
146
|
Management of multivessel coronary disease: let us not shortchange drug-eluting stents.
|
J Interv Cardiol
|
2008
|
0.75
|
|
147
|
SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies: This statement was endorsed by the American College of Cardiology (ACC), American College of Emergency Physicians (ACEP), American Heart Association (AHA), European Society of Cardiology (ESC) Association for Acute Cardiovascular Care (ACVC), International Society for Heart and Lung Transplantation (ISHLT), Society of Critical Care Medicine (SCCM), and Society of Thoracic Surgeons (STS) in December 2021.
|
J Am Coll Cardiol
|
2022
|
0.75
|
|
148
|
Reproducible microvascular dysfunction with dobutamine infusion in Takotsubo cardiomyopathy presenting with ST segment elevation.
|
Catheter Cardiovasc Interv
|
2006
|
0.75
|
|
149
|
ACCF/AHA/CDC conference report on emerging infectious diseases and biological terrorism threats: the clinical and public health implications for the prevention and control of cardiovascular diseases.
|
J Am Coll Cardiol
|
2007
|
0.75
|
|
150
|
The year in interventional cardiology.
|
J Am Coll Cardiol
|
2010
|
0.75
|
|
151
|
Impact of Contrast Dose Reduction on Incidence of Acute Kidney Injury (AKI) Among Patients Undergoing PCI: A Modeling Study.
|
J Invasive Cardiol
|
2016
|
0.75
|
|
152
|
My vision for the journal of interventional cardiology.
|
J Interv Cardiol
|
2005
|
0.75
|
|
153
|
Implications of myocardial reperfusion on survival in women versus men with acute myocardial infarction undergoing primary coronary intervention.
|
Am J Cardiol
|
2013
|
0.75
|
|
154
|
The year in interventional cardiology.
|
J Am Coll Cardiol
|
2007
|
0.75
|
|
155
|
Short-term outcomes of balloon angioplasty versus stent placement for patients undergoing primary percutaneous coronary intervention: Implications for patients requiring early coronary artery bypass surgery.
|
Am Heart J
|
2013
|
0.75
|
|
156
|
Transcatheter aortic valve replacement: The year in review 2016.
|
J Interv Cardiol
|
2017
|
0.75
|
|
157
|
Variation in hospital length of stay in patients with acute myocardial infarction undergoing primary angioplasty and the need to change the diagnostic-related group system.
|
Am J Cardiol
|
2003
|
0.75
|
|
158
|
The year in interventional cardiology.
|
J Am Coll Cardiol
|
2006
|
0.75
|
|
159
|
Outcomes of bail-out stenting for suboptimal balloon angioplasty during primary intervention in acute myocardial infarction (The CADILLAC trial).
|
Am J Cardiol
|
2003
|
0.75
|
|
160
|
Impact of worsening renal dysfunction on the comparative efficacy of bivalirudin and platelet glycoprotein IIb/IIIa inhibitors: insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium.
|
Circ Cardiovasc Interv
|
2013
|
0.75
|
|
161
|
Impact of interventionalist volume, experience, and board certification on coronary angioplasty outcomes in the era of stenting.
|
Am J Cardiol
|
2004
|
0.75
|
|
162
|
The year in interventional cardiology.
|
J Am Coll Cardiol
|
2008
|
0.75
|
|
163
|
ACCF/AHA/CDC conference report on emerging infectious diseases and biological terrorism threats: the clinical and public health implications for the prevention and control of cardiovascular diseases.
|
Circulation
|
2007
|
0.75
|
|
164
|
Percutaneous intervention of unprotected left main coronary artery.
|
J Interv Cardiol
|
2003
|
0.75
|
|
165
|
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy.
|
J Interv Cardiol
|
2005
|
0.75
|
|
166
|
Computed tomographic angiographic morphology of invasively proven complex coronary plaques.
|
JACC Cardiovasc Imaging
|
2008
|
0.75
|
|
167
|
Transradial for complex coronary interventions: breaking the glass ceiling in coronary interventions.
|
J Interv Cardiol
|
2014
|
0.75
|